182 related articles for article (PubMed ID: 31805750)
1. Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study.
Calura E; Ciciani M; Sambugaro A; Paracchini L; Benvenuto G; Milite S; Martini P; Beltrame L; Zane F; Fruscio R; Marchette MD; Borella F; Tognon G; Ravaggi A; Katsaros D; Bignotti E; Odicino F; D'Incalci M; Marchini S; Romualdi C
Cells; 2019 Dec; 8(12):. PubMed ID: 31805750
[TBL] [Abstract][Full Text] [Related]
2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
3. MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities.
Calura E; Fruscio R; Paracchini L; Bignotti E; Ravaggi A; Martini P; Sales G; Beltrame L; Clivio L; Ceppi L; Di Marino M; Fuso Nerini I; Zanotti L; Cavalieri D; Cattoretti G; Perego P; Milani R; Katsaros D; Tognon G; Sartori E; Pecorelli S; Mangioni C; D'Incalci M; Romualdi C; Marchini S
Clin Cancer Res; 2013 Aug; 19(15):4114-23. PubMed ID: 23766361
[TBL] [Abstract][Full Text] [Related]
4. Histological Grade and Tumor Stage Are Correlated with Expression of Receptor Activator of Nuclear Factor Kappa b (Rank) in Epithelial Ovarian Cancers.
Gomez R; Tejada MÁ; Rodríguez-García V; Burgués O; Santos-Llamas AI; Martínez-Massa A; Marín-Montes A; Tarín JJ; Cano A
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163671
[TBL] [Abstract][Full Text] [Related]
5. An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response.
Pinciroli P; Alberti C; Sensi M; Canevari S; Tomassetti A
BMC Genomics; 2013 Jul; 14():508. PubMed ID: 23889749
[TBL] [Abstract][Full Text] [Related]
6. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
7. lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study.
Martini P; Paracchini L; Caratti G; Mello-Grand M; Fruscio R; Beltrame L; Calura E; Sales G; Ravaggi A; Bignotti E; Odicino FE; Sartori E; Perego P; Katsaros D; Craparotta I; Chiorino G; Cagnin S; Mannarino L; Ceppi L; Mangioni C; Ghimenti C; D'Incalci M; Marchini S; Romualdi C
Clin Cancer Res; 2017 May; 23(9):2356-2366. PubMed ID: 27827314
[No Abstract] [Full Text] [Related]
8. Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.
Mackenzie R; Talhouk A; Eshragh S; Lau S; Cheung D; Chow C; Le N; Cook LS; Wilkinson N; McDermott J; Singh N; Kommoss F; Pfisterer J; Huntsman DG; Köbel M; Kommoss S; Gilks CB; Anglesio MS
Am J Surg Pathol; 2015 Nov; 39(11):1548-57. PubMed ID: 26099008
[TBL] [Abstract][Full Text] [Related]
9. ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer.
Jung M; Gao J; Cheung L; Bongers A; Somers K; Clifton M; Ramsay EE; Russell AJ; Valli E; Gifford AJ; George J; Kennedy CJ; Wakefield MJ; Topp M; Ho GY; ; Scott CL; Bowtell DD; deFazio A; Norris MD; Haber M; Henderson MJ
Int J Cancer; 2020 Oct; 147(8):2225-2238. PubMed ID: 32277480
[TBL] [Abstract][Full Text] [Related]
10. Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes.
Earp MA; Raghavan R; Li Q; Dai J; Winham SJ; Cunningham JM; Natanzon Y; Kalli KR; Hou X; Weroha SJ; Haluska P; Lawrenson K; Gayther SA; Wang C; Goode EL; Fridley BL
Oncotarget; 2017 Jul; 8(29):46891-46899. PubMed ID: 28423358
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
Zeng S; Liu S; Feng J; Gao J; Xue F
Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
[TBL] [Abstract][Full Text] [Related]
12. Circular RNA profiling reveals circEXOC6B and circN4BP2L2 as novel prognostic biomarkers in epithelial ovarian cancer.
Ning L; Long B; Zhang W; Yu M; Wang S; Cao D; Yang J; Shen K; Huang Y; Lang J
Int J Oncol; 2018 Dec; 53(6):2637-2646. PubMed ID: 30272264
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive investigation of histotype-specific microRNA and their variants in Stage I epithelial ovarian cancers.
Velle A; Pesenti C; Grassi T; Beltrame L; Martini P; Jaconi M; Agostinis F; Calura E; Katsaros D; Borella F; Fruscio R; D'Incalci M; Marchini S; Romualdi C
Int J Cancer; 2023 May; 152(9):1989-2001. PubMed ID: 36541726
[TBL] [Abstract][Full Text] [Related]
14. [Can new molecular profiles in epithelial ovarian cancer modify therapeutics?].
Lavoué V; Rousselin A; Delplanque S; Pinsard M; Henno S; Foucher F; Levêque J; de la Motte Rouge T
J Gynecol Obstet Hum Reprod; 2017 Feb; 46(2):107-112. PubMed ID: 28403964
[TBL] [Abstract][Full Text] [Related]
15. Transcription factors in epithelial ovarian cancer: histotype-specific drivers and novel therapeutic targets.
Nameki R; Chang H; Reddy J; Corona RI; Lawrenson K
Pharmacol Ther; 2021 Apr; 220():107722. PubMed ID: 33137377
[TBL] [Abstract][Full Text] [Related]
16. Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes.
Zhu S; Zhang C; Cao D; Bai J; Yu S; Chen J; Wang J; Ren T; Yang J; Yu M; Xiao X; Gong Y; Guan Y; Li P; Yue Y; Yin R; Wang Y; An R; Lou G; Yuan J; Zhang G; Xia X; Yang L; Xiang Y
Oncogene; 2022 May; 41(22):3093-3103. PubMed ID: 35468938
[TBL] [Abstract][Full Text] [Related]
17. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.
Hampras SS; Sucheston-Campbell LE; Cannioto R; Chang-Claude J; Modugno F; Dörk T; Hillemanns P; Preus L; Knutson KL; Wallace PK; Hong CC; Friel G; Davis W; Nesline M; Pearce CL; Kelemen LE; Goodman MT; Bandera EV; Terry KL; Schoof N; Eng KH; Clay A; Singh PK; Joseph JM; Aben KK; Anton-Culver H; Antonenkova N; Baker H; Bean Y; Beckmann MW; Bisogna M; Bjorge L; Bogdanova N; Brinton LA; Brooks-Wilson A; Bruinsma F; Butzow R; Campbell IG; Carty K; Cook LS; Cramer DW; Cybulski C; Dansonka-Mieszkowska A; Dennis J; Despierre E; Dicks E; Doherty JA; du Bois A; Dürst M; Easton D; Eccles D; Edwards RP; Ekici AB; Fasching PA; Fridley BL; Gao YT; Gentry-Maharaj A; Giles GG; Glasspool R; Gronwald J; Harrington P; Harter P; Hasmad HN; Hein A; Heitz F; Hildebrandt MA; Hogdall C; Hogdall E; Hosono S; Iversen ES; Jakubowska A; Jensen A; Ji BT; Karlan BY; Kellar M; Kelley JL; Kiemeney LA; Klapdor R; Kolomeyevskaya N; Krakstad C; Kjaer SK; Kruszka B; Kupryjanczyk J; Lambrechts D; Lambrechts S; Le ND; Lee AW; Lele S; Leminen A; Lester J; Levine DA; Liang D; Lissowska J; Liu S; Lu K; Lubinski J; Lundvall L; Massuger LF; Matsuo K; McGuire V; McLaughlin JR; McNeish I; Menon U; Moes-Sosnowska J; Narod SA; Nedergaard L; Nevanlinna H; Nickels S; Olson SH; Orlow I; Weber RP; Paul J; Pejovic T; Pelttari LM; Perkins B; Permuth-Wey J; Pike MC; Plisiecka-Halasa J; Poole EM; Risch HA; Rossing MA; Rothstein JH; Rudolph A; Runnebaum IB; Rzepecka IK; Salvesen HB; Schernhammer E; Schmitt K; Schwaab I; Shu XO; Shvetsov YB; Siddiqui N; Sieh W; Song H; Southey MC; Tangen IL; Teo SH; Thompson PJ; Timorek A; Tsai YY; Tworoger SS; Tyrer J; van Altena AM; Vergote I; Vierkant RA; Walsh C; Wang-Gohrke S; Wentzensen N; Whittemore AS; Wicklund KG; Wilkens LR; Wu AH; Wu X; Woo YL; Yang H; Zheng W; Ziogas A; Gayther SA; Ramus SJ; Sellers TA; Schildkraut JM; Phelan CM; Berchuck A; Chenevix-Trench G; Cunningham JM; Pharoah PP; Ness RB; Odunsi K; Goode EL; Moysich KB
Oncotarget; 2016 Oct; 7(43):69097-69110. PubMed ID: 27533245
[TBL] [Abstract][Full Text] [Related]
18. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam P
Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
[TBL] [Abstract][Full Text] [Related]
19. Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers.
Kawakami E; Tabata J; Yanaihara N; Ishikawa T; Koseki K; Iida Y; Saito M; Komazaki H; Shapiro JS; Goto C; Akiyama Y; Saito R; Saito M; Takano H; Yamada K; Okamoto A
Clin Cancer Res; 2019 May; 25(10):3006-3015. PubMed ID: 30979733
[TBL] [Abstract][Full Text] [Related]
20. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
